vs
loanDepot, Inc.（LDI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
loanDepot, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$310.3M vs $207.3M），loanDepot, Inc.净利率更高（-7.2% vs -62.0%，领先54.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 20.5%），Ultragenyx Pharmaceutical Inc.自由现金流更多（$-100.8M vs $-648.0M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 18.0%）
loanDepot, Inc.是一家总部位于美国加利福尼亚州欧文市的非银行控股公司，主营抵押贷款及其他非抵押类贷款产品的销售业务，是美国市场上颇具规模的消费信贷服务提供商。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
LDI vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $310.3M | $207.3M |
| 净利润 | $-22.5M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | -10.3% | -54.7% |
| 净利率 | -7.2% | -62.0% |
| 营收同比 | 20.5% | 25.9% |
| 净利润同比 | 32.4% | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $310.3M | $207.3M | ||
| Q3 25 | $323.3M | $159.9M | ||
| Q2 25 | $282.5M | $166.5M | ||
| Q1 25 | $273.6M | $139.3M | ||
| Q4 24 | $257.5M | $164.6M | ||
| Q3 24 | $314.6M | $139.5M | ||
| Q2 24 | $265.4M | $147.0M | ||
| Q1 24 | $222.8M | $108.8M |
| Q4 25 | $-22.5M | $-128.6M | ||
| Q3 25 | $-4.9M | $-180.4M | ||
| Q2 25 | $-13.4M | $-115.0M | ||
| Q1 25 | $-21.9M | $-151.1M | ||
| Q4 24 | $-33.2M | $-133.2M | ||
| Q3 24 | $1.4M | $-133.5M | ||
| Q2 24 | $-32.2M | $-131.6M | ||
| Q1 24 | $-34.3M | $-170.7M |
| Q4 25 | -10.3% | -54.7% | ||
| Q3 25 | -3.2% | -106.9% | ||
| Q2 25 | -11.4% | -64.8% | ||
| Q1 25 | -16.8% | -102.6% | ||
| Q4 24 | -32.7% | -74.3% | ||
| Q3 24 | 1.1% | -94.6% | ||
| Q2 24 | -29.1% | -79.1% | ||
| Q1 24 | -38.2% | -151.9% |
| Q4 25 | -7.2% | -62.0% | ||
| Q3 25 | -1.5% | -112.8% | ||
| Q2 25 | -4.7% | -69.0% | ||
| Q1 25 | -8.0% | -108.5% | ||
| Q4 24 | -12.9% | -80.9% | ||
| Q3 24 | 0.4% | -95.7% | ||
| Q2 24 | -12.1% | -89.5% | ||
| Q1 24 | -15.4% | -156.8% |
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | $0.01 | $-1.40 | ||
| Q2 24 | $-0.18 | $-1.52 | ||
| Q1 24 | $-0.19 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $337.2M | $421.0M |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $386.0M | $-80.0M |
| 总资产 | $6.9B | $1.5B |
| 负债/权益比越低杠杆越低 | 5.44× | — |
8季度趋势，按日历期对齐
| Q4 25 | $337.2M | $421.0M | ||
| Q3 25 | $459.2M | $202.5M | ||
| Q2 25 | $408.6M | $176.3M | ||
| Q1 25 | $371.5M | $127.1M | ||
| Q4 24 | $421.6M | $174.0M | ||
| Q3 24 | $483.0M | $150.6M | ||
| Q2 24 | $533.2M | $480.7M | ||
| Q1 24 | $603.7M | $112.3M |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.3B | — |
| Q4 25 | $386.0M | $-80.0M | ||
| Q3 25 | $433.3M | $9.2M | ||
| Q2 25 | $439.1M | $151.3M | ||
| Q1 25 | $469.3M | $144.2M | ||
| Q4 24 | $506.6M | $255.0M | ||
| Q3 24 | $592.0M | $346.8M | ||
| Q2 24 | $578.9M | $432.4M | ||
| Q1 24 | $637.3M | $140.3M |
| Q4 25 | $6.9B | $1.5B | ||
| Q3 25 | $6.2B | $1.2B | ||
| Q2 25 | $6.2B | $1.3B | ||
| Q1 25 | $6.4B | $1.3B | ||
| Q4 24 | $6.3B | $1.5B | ||
| Q3 24 | $6.4B | $1.5B | ||
| Q2 24 | $5.9B | $1.6B | ||
| Q1 24 | $6.2B | $1.3B |
| Q4 25 | 5.44× | — | ||
| Q3 25 | 4.83× | — | ||
| Q2 25 | 4.70× | — | ||
| Q1 25 | 4.30× | — | ||
| Q4 24 | 4.00× | — | ||
| Q3 24 | 3.31× | — | ||
| Q2 24 | 3.41× | — | ||
| Q1 24 | 3.63× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-638.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-648.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | -208.9% | -48.6% |
| 资本支出强度资本支出/营收 | 3.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-734.6M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-638.7M | $-99.8M | ||
| Q3 25 | $43.4M | $-91.4M | ||
| Q2 25 | $67.6M | $-108.3M | ||
| Q1 25 | $-179.9M | $-166.5M | ||
| Q4 24 | $47.7M | $-79.3M | ||
| Q3 24 | $-349.2M | $-67.0M | ||
| Q2 24 | $-278.3M | $-77.0M | ||
| Q1 24 | $-278.5M | $-190.7M |
| Q4 25 | $-648.0M | $-100.8M | ||
| Q3 25 | $38.7M | $-92.7M | ||
| Q2 25 | $61.4M | $-110.7M | ||
| Q1 25 | $-186.7M | $-167.8M | ||
| Q4 24 | $40.8M | $-79.5M | ||
| Q3 24 | $-356.4M | $-68.6M | ||
| Q2 24 | $-285.7M | $-79.0M | ||
| Q1 24 | $-283.3M | $-193.9M |
| Q4 25 | -208.9% | -48.6% | ||
| Q3 25 | 12.0% | -58.0% | ||
| Q2 25 | 21.7% | -66.5% | ||
| Q1 25 | -68.2% | -120.5% | ||
| Q4 24 | 15.8% | -48.3% | ||
| Q3 24 | -113.3% | -49.2% | ||
| Q2 24 | -107.7% | -53.7% | ||
| Q1 24 | -127.2% | -178.2% |
| Q4 25 | 3.0% | 0.5% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 2.5% | 1.0% | ||
| Q4 24 | 2.7% | 0.1% | ||
| Q3 24 | 2.3% | 1.2% | ||
| Q2 24 | 2.8% | 1.4% | ||
| Q1 24 | 2.1% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -255.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LDI
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
